Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%
Lupin Limited secures FDA approval for Loteprednol Etabonate Ophthalmic Gel, enhancing treatment options for postoperative ocular inflammation and pain.
Lupin Limited recently announced the US Food and Drug Administration (FDA) approval for the company’s Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Gel, 0.38%.1
Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid for the treatment of postoperative inflammation and pain following ocular surgery. It is the bioequivalent to Bausch & Lomb’s Lotemax SM Ophthalmic Gel. Additionally, Loteprednol Etabonate Ophthalmic Gel, 0.38% had an estimated annual sale of $29 million in the US, according to a press release.
Lupin is eligible for 180 days of drug exclusivity, as the company is the exclusive first-to-file for the product.
Reference:
kw2023. Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China. Lupin. Published July 2025. Accessed July 1, 2025.
https://www.lupin.com/lupin-receives-approval-from-u-s-fda-for-loteprednol-etabonate-ophthalmic-gel/
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Articles
- The European Commission grants marketing authorization for EYLUXVI
September 23rd 2025
- Luxa Biotechnology announces clinical trial results for treatment of AMD
September 22nd 2025